Point72 Asset Management
REGN icon

Point72 Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Point72 Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Sell
1,000
-142,800
-99% -$97.2M ﹤0.01% 3080
2026
Q1 		$111M Buy
143,800
+142,900
+15,878% +$109M 0.14% 150
2025
Q4 		$695K Buy
+900
New +$611K ﹤0.01% 3064
2024
Q4 		– Sell
-2,200
Closed -$2.31M – 2387
2024
Q3 		$2.31M Buy
+2,200
New +$2.45M 0.01% 1141

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Point72 Asset Management's REGN Position: Q2 2026 in Review

Point72 Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 2,175 shares — an estimated $1.48M sold.

Point72 Asset Management first reported a position in REGN in Q2 2014 and held it in 18 quarters. The position peaked at $203M in Q4 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Point72 Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Point72 Asset Management sold 2,175 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.48M.
  • Point72 Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2014 and held it in 18 quarters.
  • Point72 Asset Management's Regeneron Pharmaceuticals position peaked at $203M in Q4 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.